Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization
Abstract
:1. Introduction
2. Results
2.1. PD-L1 Testing in Routine Practice
2.2. Concordance of Image Analysis and Manual PD-L1 IHC Assessment
2.3. Challenges of Image Analysis on Routine PD-L1 IHC
2.4. Comparative Analysis and Utility of PD-L1 Multiplexing
3. Discussion
4. Materials and Methods
4.1. Clinical Samples
4.2. Routine Diagnostic Staining
4.3. PD-L1 IHC Image Analysis
4.4. Multiplex Staining
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Gong, J.; Chehrazi-Raffle, A.; Reddi, S.; Salgia, R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations. J. Immunother. Cancer 2018, 6, 8. [Google Scholar] [CrossRef] [PubMed]
- Taube, J.M.; Klein, A.; Brahmer, J.R.; Xu, H.; Pan, X.; Kim, J.H.; Chen, L.; Pardoll, D.M.; Topalian, S.L.; Anders, R.A. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014, 20, 5064–5074. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Taube, J.M.; Galon, J.; Sholl, L.M.; Rodig, S.J.; Cottrell, T.R.; Giraldo, N.A.; Baras, A.S.; Patel, S.S.; Anders, R.A.; Rimm, D.L.; et al. Implications of the tumor immune microenvironment for staging and therapeutics. Mod. Pathol. 2018, 31, 214–234. [Google Scholar] [CrossRef] [PubMed]
- Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; et al. Safety, activity, and immune correlates of Anti–PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366, 2443–2454. [Google Scholar] [CrossRef] [PubMed]
- Humphries, M.P.; McQuaid, S.; Craig, S.G.; Bingham, V.; Maxwell, P.; Maurya, M.; McLean, F.; Sampson, J.; Higgins, P.; Greene, C.; et al. Critical appraisal of programmed death ligand 1 reflex diagnostic testing: Current standards and future opportunities. J. Thorac. Oncol. 2019, 14, 45–53. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Teixidó, C.; Vilariño, N.; Reyes, R.; Reguart, N. PD-L1 expression testing in non-small cell lung cancer. Ther. Adv. Med. Oncol. 2018, 10, 1758835918763493. [Google Scholar] [CrossRef] [PubMed]
- Lantuejoul, S.; Damotte, D.; Hofman, V.; Adam, J. Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. J. Thorac. Dis. 2019, 11, S89–S101. [Google Scholar] [CrossRef] [PubMed]
- Hersom, M.; Jorgensen, J.T. Companion and complementary diagnostics-focus on PD-L1 expression assays for PD-1/PD-L1 checkpoint inhibitors in non-small cell lung cancer. Ther. Drug Monit. 2018, 40, 9–16. [Google Scholar] [PubMed]
- Rimm, D.L.; Han, G.; Taube, J.M.; Yi, E.S.; Bridge, J.A.; Flieder, D.B.; Homer, R.; West, W.W.; Wu, H.; Roden, A.C.; et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in Non–Small cell lung cancer assessment of 4 assays for PD-L1 expression in NSCLCAssessment of 4 assays for PD-L1 expression in NSCLC. Oncology 2017, 3, 1051–1058. [Google Scholar]
- Herbst, R.S.; Soria, J.C.; Kowanetz, M.; Fine, G.D.; Hamid, O.; Gordon, M.S.; Sosman, J.A.; McDermott, D.F.; Powderly, J.D.; Gettinger, S.N.; et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515, 563–567. [Google Scholar] [CrossRef] [Green Version]
- Aguiar, P.N., Jr.; De Mello, R.A.; Hall, P.; Tadokoro, H.; Lima Lopes, G. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: Updated survival data. Immunotherapy 2017, 9, 499–506. [Google Scholar] [CrossRef] [PubMed]
- Gibney, G.T.; Weiner, L.M.; Atkins, M.B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016, 17, e542–e551. [Google Scholar] [CrossRef] [Green Version]
- Lu, S.; Stein, J.E.; Rimm, D.L.; Wang, D.W.; Bell, J.M.; Johnson, D.B.; Sosman, J.A.; Schalper, K.A.; Anders, R.A.; Wang, H.; et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: A systematic review and meta-analysis. JAMA Oncol. 2019, 5, 1195–1204. [Google Scholar] [CrossRef] [PubMed]
- Taylor, C.R.; Jadhav, A.P.; Gholap, A.; Kamble, G.; Huang, J.; Gown, A.; Doshi, I.; Rimm, D.L. A multi-institutional study to evaluate automated whole slide scoring of immunohistochemistry for assessment of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Appl. Immunohistochem. Mol. Morphol. 2019, 27, 263–269. [Google Scholar] [CrossRef] [PubMed]
- Mattocks, C.J.; Morris, M.A.; Matthijs, G.; Swinnen, E.; Corveleyn, A.; Dequeker, E.; Muller, C.R.; Pratt, V.; Wallace, A.; EuroGentest Validation Group. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur. J. Hum. Genet. 2010, 18, 1276–1288. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Widmaier, M.; Wiestler, T.; Walker, J.; Barker, C.; Scott, M.L.; Sekhavati, F.; Budco, A.; Schneider, K.; Segerer, F.J.; Steele, K.; et al. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis. Mod. Pathol. 2020, 33, 380–390. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bankhead, P.; Fernandez, J.A.; McArt, D.G.; Boyle, D.P.; Li, G.; Loughrey, M.B.; Irwin, G.W.; Harkin, D.P.; James, J.A.; McQuaid, S.; et al. Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer. Lab. Invest. 2018, 98, 15–26. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bankhead, P.; Loughrey, M.B.; Fernandez, J.A.; Dombrowski, Y.; McArt, D.G.; Dunne, P.D.; McQuaid, S.; Gray, R.T.; Murray, L.J.; Coleman, H.G. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 2017, 7, 16878. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Loughrey, M.B.; Bankhead, P.; Coleman, H.G.; Hagan, R.S.; Craig, S.; McCorry, A.M.B.; Gray, R.T.; McQuaid, S.; Dunne, P.D.; Hamilton, P.W. Validation of the systematic scoring of immunohistochemically-stained tumour tissue microarrays using QuPath digital image analysis. Histopathology 2018, 73, 327–338. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Humphries, M.P.; Hynes, S.; Bingham, V.; Cougot, D.; James, J.; Patel-Socha, F.; Parkes, E.E.; Blayney, J.K.; O’Rorke, M.A.; Irwin, G.W.; et al. Automated tumour recognition and digital pathology scoring unravels new role for PD-L1 in predicting good outcome in ER-/HER2+ breast cancer. J. Oncol. 2018, 2018, 2937012. [Google Scholar] [CrossRef] [PubMed]
Reasons for Discordance | Number of Cases |
---|---|
Classifier | 22 |
Macrophages | 8 |
Spurious Staining | 41 |
Threshold sensitivity | 55 |
PD-L1 DAB IHC | ||||
---|---|---|---|---|
Positive | Negative | Total | ||
PD-L1 Multiplex | Positive | 141 | 15 | 156 |
Negative | 4 | 170 | 174 | |
Total | 145 | 185 | 330 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Humphries, M.P.; Bingham, V.; Abdullahi Sidi, F.; Craig, S.G.; McQuaid, S.; James, J.; Salto-Tellez, M. Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization. Cancers 2020, 12, 1114. https://doi.org/10.3390/cancers12051114
Humphries MP, Bingham V, Abdullahi Sidi F, Craig SG, McQuaid S, James J, Salto-Tellez M. Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization. Cancers. 2020; 12(5):1114. https://doi.org/10.3390/cancers12051114
Chicago/Turabian StyleHumphries, Matthew P., Victoria Bingham, Fatima Abdullahi Sidi, Stephanie G. Craig, Stephen McQuaid, Jacqueline James, and Manuel Salto-Tellez. 2020. "Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization" Cancers 12, no. 5: 1114. https://doi.org/10.3390/cancers12051114